Repurposing CRISPR/Cas9 for in situ functional assays - PubMed (original) (raw)
Repurposing CRISPR/Cas9 for in situ functional assays
Abba Malina et al. Genes Dev. 2013.
Abstract
RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle target, we readapted the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated 9) genome-editing system to demonstrate the feasibility of this methodology for targeted gene disruption positive selection assays. By using novel "all-in-one" lentiviral and retroviral delivery vectors heterologously expressing both a codon-optimized Cas9 and its synthetic guide RNA (sgRNA), we show robust selection for the CRISPR-modified Trp53 locus following drug treatment. Furthermore, by linking Cas9 expression to GFP fluorescence, we use an "all-in-one" system to track disrupted Trp53 in chemoresistant lymphomas in the Eμ-myc mouse model. Deep sequencing analysis of the tumor-derived endogenous Cas9-modified Trp53 locus revealed a wide spectrum of mutants that were enriched with seemingly limited off-target effects. Taken together, these results establish Cas9 genome editing as a powerful and practical approach for positive in situ genetic screens.
Keywords: CRISPR; Cas9; functional screening; genome editing; p53.
Figures
Figure 1.
Genome editing of a TLR locus in 293T cells using an engineered all-in-one type II CRISPR system. (A) Schematic diagram of LeGO-based lentivirus (pLC) constructs driving expression of Cas9 and sgRNAs. (B) Predicted secondary structure (
http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi
) of sgRNA showing alignment of trigger sequence with target and PAM. The first nucleotide of the trigger sequence is forcibly a G, since the sgRNA is expressed from the murine U6 promoter. (C) Schematic of TLR with the position and nucleotide sequence of the TLR trigger, PAM, and stop codon shown. (D) A genomically integrated TLR is efficiently targeted by pLC-TLR. Quantitation of 293T TLR cells transfected with the indicated Cas9/sgRNA expression constructs and, where indicated, in combination with Δ20 eGFP. (E) Immunoblot showing expression and subcellular localization of Cas9 from the experiment presented in D. (C) Cytoplasmic fraction; (M) membrane fraction; (N) nuclear fraction. Blots were probed with the antibodies indicated below each panel. (F) Lentiviral-mediated NHEJ and HDR in 293T TLR cells. Cells were infected with lentivirus expressing Cas9 and the corresponding sgRNA and analyzed by flow cytometry 6 d later. The Δ20 eGFP donor plasmid was introduced by transfection 1 d prior to transduction with the Cas9/sgRNA lentiviral construct.
Figure 2.
Cas9-mediated editing of _Trp_53 in _Arf_−/− MEFs leads to Nutlin-3a resistance. (A) Schematic diagram of the pQ-based retroviral constructs driving expression of Cas9, GFP, and sgRNAs (pQCiG). (B) Flow cytometric analysis of _Arf_−/− and _p53_−/− MEFs transduced with QCiG-Rosa, QCiG-p53, or MLP-p53.1224 retroviruses, cultured 3 d later in the presence of vehicle or 10 μM Nutlin-3a for 24 h, and then allowed to recover for 4 d. (C) Colony formation assay of infected _Arf_−/− and _p53_−/− MEFs with QCiG-Rosa, QCiG-p53, or MLP-p53.1224. Five-thousand cells were seeded, exposed to 10 μM Nutlin-3a for 24 h, and allowed to recover for 12 d in the absence of drug, at which point they were stained with crystal violet. (D) SURVEYOR assay of DNA isolated from QCiG-p53- and QCiG-Rosa-infected _Arf_−/− MEFs exposed to 10 μM Nutlin-3a for 24 h and allowed to recover for 4 d. The arrowhead denotes the expected SURVEYOR cleavage products. (E) Immunoblot documenting Cas9 and p53 expression in QCiG- and MLP-infected MEFs. The asterisk denotes the position of a prominent p53 truncated product.
Figure 3.
Cas9-mediated editing of _Trp_53 in _Arf_−/−Eμ-myc lymphomas is positively selected for following DXR treatment in vivo. (A) Schematic diagram of in vivo fitness assay. (B) Kaplan-Meier analysis of tumor-free survival of mice injected with Rosa26 or Trp53 Cas9 targeted _Arf_−/−Eμ-myc and _p53_−/−Eμ-myc lymphomas following treatment with DXR. (C) Detection of GFP in tumors arising from QCiG-p53-infected _Arf_−/−Eμ-myc lymphomas following exposure to DXR and analyzed 3 d later. White arrows denote GFP fluorescence in lymph nodes originating from the presence of QCiG-p53 in the resulting tumors. (D) FACS analysis of the indicated Cas9 targeted Eμ-myc lymphomas analyzed before injection into mice (input), from tumors arising in vivo (pre-DXR), and from tumors for which the host had received DXR treatment (post-DXR). (E) SURVEYOR assay of DNA from QCiG-p53- and QCiG-Rosa-infected _Arf_−/−Eμ-myc lymphomas isolated from mice prior to DXR treatment. (F) Immunoblot showing long-term Cas9, p53, and GFP expression in QCiG-Rosa and QCiG-p53 Arf_−/−_Eμ-Myc lymphomas in vivo. Samples are from three separate tumors isolated prior to (pre-DXR) or following (post-DXR) DXR treatment. In the case of post-DXR samples for QCiG-Rosa _Arf_−/−Eμ-myc lymphomas, tumors were harvested after relapse (∼10 d after post-DXR treatment). The asterisk highlights a truncated p53 protein arising in the Cas9-edited samples.
Figure 4.
Analysis of indels at the Trp53 locus and at predicted off-target sites in _Arf_−/−MEFs and _Arf_−/−Eμ-myc tumors edited with Rosa26 and _Trp5_3 sgRNAs. (A) Total count and location of insertions and deletions in exon 7 of Trp53 in _Arf_−/−Eμ-myc cells prior to injection, post-implantation, and post-DXR treatment, respectively. The vertical dashed line represents the predicted Cas9 cleavage site. (B) Frequency of mutant reads obtained following sequencing of Trp53 exon 7 from the indicated cells and tumors. T-1, T-2, and T-3 represent three independent tumors. (C, top panel) Sequence alignment of the trigger site in the Trp53 and Trp53 pseudogene. Differences are highlighted in green. (Bottom panel) Pie charts illustrating the proportion of mutated sequence reads at Trp53 (left) and the Trp53 pseudogene (right) relative to wild-type sequences (wt; blue). DNA was isolated from samples of _Arf_−/−Eμ-myc lymphoma cells infected with QCiG-Rosa-infected (top), QCiG-p53-infected (middle), or QCiG-p53-infected cells that were exposed to 10 μM Nutlin-3a for 3 d followed by a 10-d recovery period (bottom). (D) Prediction of genomic sequences showing sequences complementary to the first 13 perfectly matched nucleotides 5′ to the PAM of the Trp53 trigger sequence with all possible combinations of PAM. The trigger sequence is shown in blue, PAM is in red, and flanking nucleotides are in black. The genomic location is shown at the right. (E) Percent mutant reads at the indicated genomic locus in _Rosa26_- and _Trp53_-modified _Arf_−/− MEFs. The total read count for each amplified region ranged from ∼11,000 to 15,000 (sample #8), ∼18,000 to 23,000 (sample #7), and ∼20,000 to 53,000 (all others). Read counts for locus #2 are absent, since the barcode that had been used in the preparation of that sample could not be deciphered from the output of reads.
Similar articles
- A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice.
Sakurai T, Watanabe S, Kamiyoshi A, Sato M, Shindo T. Sakurai T, et al. BMC Biotechnol. 2014 Jul 21;14:69. doi: 10.1186/1472-6750-14-69. BMC Biotechnol. 2014. PMID: 25042988 Free PMC article. - CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells.
Yuen KS, Chan CP, Wong NM, Ho CH, Ho TH, Lei T, Deng W, Tsao SW, Chen H, Kok KH, Jin DY. Yuen KS, et al. J Gen Virol. 2015 Mar;96(Pt 3):626-636. doi: 10.1099/jgv.0.000012. Epub 2014 Dec 12. J Gen Virol. 2015. PMID: 25502645 - Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
Huo X, Du Y, Lu J, Guo M, Li Z, Zhang S, Li X, Chen Z, Du X. Huo X, et al. Mutat Res. 2017 Mar;797-799:1-6. doi: 10.1016/j.mrfmmm.2017.02.003. Epub 2017 Feb 28. Mutat Res. 2017. PMID: 28284774 - A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
Xu J, Ren X, Sun J, Wang X, Qiao HH, Xu BW, Liu LP, Ni JQ. Xu J, et al. J Genet Genomics. 2015 Apr 20;42(4):141-9. doi: 10.1016/j.jgg.2015.02.007. Epub 2015 Mar 12. J Genet Genomics. 2015. PMID: 25953352 Review. - Cas9, Cpf1 and C2c1/2/3-What's next?
Nakade S, Yamamoto T, Sakuma T. Nakade S, et al. Bioengineered. 2017 May 4;8(3):265-273. doi: 10.1080/21655979.2017.1282018. Epub 2017 Jan 31. Bioengineered. 2017. PMID: 28140746 Free PMC article. Review.
Cited by
- Harnessing the evolving CRISPR/Cas9 for precision oncology.
Li T, Li S, Kang Y, Zhou J, Yi M. Li T, et al. J Transl Med. 2024 Aug 8;22(1):749. doi: 10.1186/s12967-024-05570-4. J Transl Med. 2024. PMID: 39118151 Free PMC article. Review. - Development of a baculoviral CRISPR/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells.
Xiang Z, Ye Q, Zhao Z, Wang N, Li J, Zou M, Lau CH, Zhu H, Wang S, Ding Y. Xiang Z, et al. Mol Genet Genomics. 2024 Aug 1;299(1):74. doi: 10.1007/s00438-024-02167-w. Mol Genet Genomics. 2024. PMID: 39085666 - Interferon alpha and beta receptor 1 knockout in human embryonic kidney 293 cells enhances the production efficiency of proteins or adenoviral vectors related to type I interferons.
Kim A, Park JH, Lee MJ, Kim SM. Kim A, et al. Front Bioeng Biotechnol. 2023 Jul 5;11:1192291. doi: 10.3389/fbioe.2023.1192291. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37476482 Free PMC article. - The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy.
Guo N, Liu JB, Li W, Ma YS, Fu D. Guo N, et al. J Adv Res. 2022 Sep;40:135-152. doi: 10.1016/j.jare.2021.11.018. Epub 2021 Dec 4. J Adv Res. 2022. PMID: 36100322 Free PMC article. Review. - Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
Hanna A, Nixon MJ, Estrada MV, Sanchez V, Sheng Q, Opalenik SR, Toren AL, Bauer J, Owens P, Mason FM, Cook RS, Sanders ME, Arteaga CL, Balko JM. Hanna A, et al. Breast Cancer Res. 2022 Jul 18;24(1):51. doi: 10.1186/s13058-022-01542-y. Breast Cancer Res. 2022. PMID: 35850776 Free PMC article.
References
- Chang K, Elledge SJ, Hannon GJ 2006. Lessons from nature: MicroRNA-based shRNA libraries. Nat Methods 3: 707–714 - PubMed
- Cho SW, Kim S, Kim JM, Kim JS 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31: 230–232 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous